Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Novartis AG — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.87, while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Novartis AG is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| FEPI | NVS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $168.62 |
52-Week Low | $37.98 | $119.31 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $41.78, up 0.8% with a bullish technical signal from moving averages, though oscillators are neutral. The ETF provides a high yield through weekly dividends, recently transitioning to this frequency to enhance income compounding. Support and resistance are tightly clustered around $41-$42, indicating potential near-term consolidation.
Outlook: High income appeals but covered call strategy caps upside and risks NAV erosion in downturns. Opportunities include weekly cash flow for income-focused investors; risks involve concentrated tech exposure and market volatility. Analyst views are mixed, emphasizing accumulation on weakness.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
